SCHEMBL9905952

SCHEMBL9905952

CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OCC(O)CN

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 4/20 0.70
DGKA P23743 1/20 0.61
CNR1 P21554 2/20 0.59
ALDH1A1 P00352 1/20 0.59
MAPT P10636 1/20 0.59
THRB P10828 1/20 0.59
LPAR1 Q92633 7/20 0.55
LPAR4 Q99677 3/20 0.55
LPAR2 Q9HBW0 3/20 0.55
LPAR3 Q9UBY5 3/20 0.55
ENPP2 Q13822 2/20 0.55
LPAR5 Q9H1C0 2/20 0.55
CES2 O00748 1/20 0.55
LPAR6 P43657 1/20 0.55
TRPV1 Q8NER1 1/20 0.55
MGLL Q99685 1/20 0.53
GPR55 Q9Y2T6 1/20 0.53
P2RY10 O00398 3/20 0.50
GPR174 Q9BXC1 3/20 0.50
GPR34 Q9UPC5 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10037040 0.89 FAAH (0.73) FAAHDGKACNR1ALDH1A1MAPT
SCHEMBL11260384 0.89 DGKA (0.77) FAAHDGKALPAR1LPAR4LPAR2
SCHEMBL11260379 0.89 DGKA (0.77) FAAHDGKALPAR1LPAR4LPAR2
SCHEMBL23268626 0.88 FAAH (0.90) FAAHDGKACNR1ALDH1A1MAPT
SCHEMBL9905934 0.88 FAAH (0.90) FAAHDGKACNR1ALDH1A1MAPT
SCHEMBL9905946 0.87 FAAH (0.52) FAAHDGKACNR1ALDH1A1MAPT
SCHEMBL1899258 0.86 FAAH (0.82) FAAHDGKACNR1ALDH1A1MAPT
SCHEMBL15516648 0.86 FAAH (0.86) FAAHDGKACNR1ALDH1A1MAPT
SCHEMBL9905955 0.85 ALDH1A1 (0.66) FAAHDGKACNR1ALDH1A1MAPT
SCHEMBL9905962 0.85 ADORA3 (0.64) FAAHDGKACNR1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9925165-B2 Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof SCF PHARMA INC. (CA) 2018-03-27 US disclosed
US-9925165-B2 Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof SCF PHARMA INC. (CA) 2018-03-27 US disclosed
US-20170014369-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF SCF PHARMA INC. (CA) 2017-01-19 US disclosed
US-20170014369-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF SCF PHARMA INC. (CA) 2017-01-19 US disclosed
US-9480660-B2 Methods for treating inflammatory diseases with compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof SCF PHARMA INC. (CA) 2016-11-01 US disclosed
US-9480660-B2 Methods for treating inflammatory diseases with compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof SCF PHARMA INC. (CA) 2016-11-01 US disclosed
US-9233915-B2 Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof SCF PHARMA INC. (CA) 2016-01-12 US disclosed
US-9233915-B2 Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof SCF PHARMA INC. (CA) 2016-01-12 US disclosed
EP-2121576-B1 POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF CT DE RECH SUR LES BIOTECHNOLOGIES MARINE (CA) 2015-11-11 EP disclosed
US-9101563-B2 Method for treating an inflammatory disease with compositions comprising polyunsaturated fatty acid monoglycerides, derivatives thereof and uses thereof SCF PHARMA INC (CA) 2015-08-11 US disclosed
US-20100196496-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF SCF PHARMA INC. (CA) 2010-08-05 US disclosed
US-20100196496-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF SCF PHARMA INC. (CA) 2010-08-05 US disclosed
US-20100160261-A1 POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF SCF PHARMA INC. (CA) 2010-06-24 US disclosed
US-20100160261-A1 POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF SCF PHARMA INC. (CA) 2010-06-24 US disclosed
US-20090292019-A1 POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF SCF PHARMA INC. (CA) 2009-11-26 US disclosed
US-20090291102-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF SCF PHARMA INC. (CA) 2009-11-26 US disclosed
US-20090291102-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF SCF PHARMA INC. (CA) 2009-11-26 US disclosed
US-20090292019-A1 POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF SCF PHARMA INC. (CA) 2009-11-26 US disclosed
WO-2008113177-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF CENTRE DE RECHERCHE SUR LES BIOTECHNOLOGIES MARINES (CA) 2008-09-25 WO disclosed
WO-2008098375-A1 POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF CENTRE DE RECHERCHE SUR LES BIOTECHNOLOGIES MARINES (CA) 2008-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100196496-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF MGLL, PNLIP, FASN FAAH 871/4885DGKA 40/4885CNR1 3047/4885
US-20090292019-A1 POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF FASN, MGLL, FADS1 FAAH 225/4885DGKA 36/4885CNR1 2684/4885
US-20170014369-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF PPARG, PTGES, PTGIS FAAH 267/4885DGKA 102/4885CNR1 3031/4885
US-20090291102-A1 COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF MGLL, PNLIP, FASN FAAH 871/4885DGKA 40/4885CNR1 3047/4885
US-20100160261-A1 POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF FASN, MGLL, FADS1 FAAH 225/4885DGKA 36/4885CNR1 2684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.